Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ON203
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ON203 demonstrated tumor growth suppression in two cancer mouse models and superior tumor cell killing effects in vitro as compared to a first generation anti-oxMIF antibody which had reached clinical evaluation.
Product Name : ON203
Product Type : Antibody
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : ON203
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable